Valuation: Insmed Incorporated

Market Cap 23.28B 20.45B 19.02B 17.45B 32.79B 2,242B 33.29B 226B 88.22B 1,102B 87.4B 85.51B 3,811B P/E 2026 *
-42.1x
P/E 2027 * 213x
Enterprise Value 22.72B 19.95B 18.56B 17.03B 31.99B 2,188B 32.49B 220B 86.09B 1,076B 85.28B 83.45B 3,719B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 8.03x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-0.11%
1 week-1.03%
Current month+0.54%
1 month+3.61%
3 months-20.69%
6 months-32.88%
Current year-38.40%
1 week 105.09
Extreme 105.09
109.99
1 month 101.67
Extreme 101.67
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-1.03%+3.55%+423.95% 23.28B
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.53%-1.81%-21.60%-16.08% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.44%-1.12%+23.45%+178.00% 13.99B
-0.81%+15.82%+429.24%+145.45% 12.22B
Average -0.92%+2.58%+80.49%+172.38% 25.42B
Weighted average by Cap. -0.80%+2.44%+61.23%+138.68%

Financials

2026 *2027 *
Net sales 1.7B 1.49B 1.39B 1.27B 2.4B 164B 2.43B 16.5B 6.45B 80.53B 6.39B 6.25B 278B 2.78B 2.44B 2.27B 2.08B 3.91B 267B 3.97B 26.93B 10.52B 131B 10.42B 10.2B 454B
Net income -561M -493M -458M -421M -790M -54.05B -803M -5.44B -2.13B -26.58B -2.11B -2.06B -91.88B 71.64M 62.92M 58.51M 53.69M 101M 6.9B 102M 695M 271M 3.39B 269M 263M 11.73B
Net Debt -563M -495M -460M -422M -793M -54.22B -805M -5.46B -2.13B -26.66B -2.11B -2.07B -92.17B -979M -859M -799M -733M -1.38B -94.24B -1.4B -9.49B -3.71B -46.33B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-24 US$107.23 -0.17% 837,993
26-07-23 US$107.41 +0.72% 1,752,962
26-07-22 US$106.64 -1.82% 1,771,277
26-07-21 US$108.62 +1.50% 2,447,392
26-07-20 US$107.02 -1.20% 2,015,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
107.41USD
Average target price
196.18USD
Spread / Average Target
+82.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock